A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache

NCT ID: NCT01899040

Last Updated: 2025-05-31

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 100 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-08-31
• Study Completion Date: 2016-06-30

Brief Summary

This is a randomized, blinded study designed to assess the efficacy of a portable, non-invasive neuromodulation system for the treatment of episodic migraine headaches.

Detailed Description

This is a multi-center, triple-blinded, placebo-controlled, randomized pivotal trial evaluating the adjunctive prophylactic treatment of episodic migraine headache using a caloric vestibular stimulation (CVS) device developed by Scion NeuroStim, LLC (SNS). This study has been reviewed by the FDA and is categorized as posing NSR (nonsignificant risk).

Conditions

Migraine Headache, Episodic

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

active device

A standardized active neuromodulation waveform will be used for all active Device patients at all Study sites. The Device will be used twice daily.

Group Type: ACTIVE_COMPARATOR

neuromodulation for episodic migraine headache

Intervention Type: DEVICE

placebo device

A standardized placebo neuromodulation waveform will be used for all placebo Device patients at all Study sites. The Device will be used twice daily.

Group Type: PLACEBO_COMPARATOR

neuromodulation for episodic migraine headache

Intervention Type: DEVICE

Interventions

neuromodulation for episodic migraine headache

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• The patient must have been diagnosed with episodic Migraine Headache at least 6 months prior to entering into the Study, consistent with the International Headache Classification of Headache Disorders-II (ICHD-II) guidelines.
• The patient must have a history of at least three consecutive months of stable Migraine Headaches prior to entering the Study. The patients will not have had changes in medication usage for the three Months leading up to the Study, nor will they introduce new medications during the Study period. Patients will satisfy these criteria: On a Monthly basis, at least four, and not more than a total of fourteen (4-14), Headache Days (Pain Score between one and ten) of which between four and nine (4-14) are Migraine Headache Days
• The patient must not have failed on more than two classes of properly administered prophylactic pharmaceutical therapies for migraine headache. The patient may be on a single migraine prophylactic as long as the dosage has not been altered within 3 months of starting the study and the dosage must not be altered for the duration of the study.
• The Investigator must have confidence in the patient's ability to reliably use the Experimental Device and promptly complete the Daily Headache Diary forms. The Daily Headache Diary will be completed from the beginning of the Pre-Treatment Baseline Period through the end of the Pivotal Study.

Exclusion Criteria

Individuals who:

• are pregnant
• have a history of cardiovascular disease
• work night shifts
• have been diagnosed with vestibular migraine
• have been diagnosed with migraine with aura
• have menstrual migraine exclusively
• have been diagnosed with post-traumatic migraine
• have a history of unstable mood disorder or unstable anxiety disorder
• use a hearing aid
• have a cochlear implant
• have chronic tinnitus
• have temporomandibular joint (TMJ) disease
• have been diagnosed with traumatic brain injury (TBI)
• have been diagnosed with neurological disease other than Headaches
• have a diagnosed vestibular dysfunction
• abuse alcohol or other drugs
• are experiencing medication overuse Headaches (individuals with respect to whom the Investigator is concerned that analgesic abuse is involved based on the ICHD-II guidelines).
• are younger than 18 years or older than 65 years
• have had eye surgery within the previous three months or ear surgery within the previous six months
• have active ear infections or a perforated tympanic membrane
• have participated in another clinical trial within the last 30 days or are currently enrolled in another clinical trial
• are using Botox treatments for migraines
• Though not excluded, patients taking anti-histamines or anti-nausea drugs will be encouraged not to take such medications within four hours prior to using the Device. The Investigator should review other medications taken by the patient with properties that mimic anti-nausea or anti-dizziness drugs as these may reduce responsiveness to stimulation. Such medications should also be avoided within four hours prior to a treatment.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Scion NeuroStim

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Lesco Rogers, MD

Role: STUDY_DIRECTOR

Scion NeuroStim

Locations

Naval Medical Center

San Diego, California, United States

Michigan Headache and Neurological Institute

Ann Arbor, Michigan, United States

Carolina Headache Institute

Chapel Hill, North Carolina, United States

Duke University

Durham, North Carolina, United States

Headache Wellness Center

Greensboro, North Carolina, United States

Kent University

Canterbury, Kent, United Kingdom

Countries

United States; United Kingdom

References

Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, Smith LL, Poynter KP, Laskowitz DT, Freeman MC, Hoffer ME, Saper JR, Scott DL, Sakel M, Calhoun AH, Black RD. Preventing Episodic Migraine With Caloric Vestibular Stimulation: A Randomized Controlled Trial. Headache. 2017 Jul;57(7):1065-1087. doi: 10.1111/head.13120. Epub 2017 Jun 27.

Reference Type: DERIVED

PMID: 28656612 (View on PubMed)

Provided Documents

Document Type: Study Protocol and Statistical Analysis Plan

View Document

Other Identifiers

SNS-MIG-01

Identifier Type: -

Identifier Source: org_study_id